Abstract Number: 2073 • ACR Convergence 2025
Cell-free DNA as a Potential Marker of Muscle Involvement and Treatment Response in Myositis
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by inflammatory muscle injury. Circulating cell-free DNA (cfDNA), including nuclear (cfnDNA) and mitochondrial (cfmtDNA) DNA, has been shown…Abstract Number: 1826 • ACR Convergence 2025
Single Nuclei Multiome of JDM Muscle Biopsies Reveals Novel Upregulation of Inflammatory and Vascular Pathways
Background/Purpose: Juvenile dermatomyositis (JDM) is a multisystem vasculopathy and inflammatory myopathy characterized by proximal muscle weakness, distinct rash, and risk of long-term complications such as…Abstract Number: 1211 • ACR Convergence 2025
Plasma Levels of miR-133a-3p and miR-1-3p as Potential Biomarkers of Muscle Involvement and Initial Treatment Response in Myositis
Background/Purpose: Idiopathic inflammatory myopathies (IIM) involve muscle inflammation. MicroRNAs (miRNAs), such as miR-133a-3p and miR-1-3p, play a key role in gene regulation and muscle repair.…Abstract Number: 1204 • ACR Convergence 2025
Validity and reliability of a new ultrasound-based semiquantitative echogenicity grading scale for myositis.
Background/Purpose: The Heckmatt grading scale has been widely used as a semiquantitative assessment method for grading muscle echo intensity (EI) on ultrasound; however, this was…Abstract Number: 0999 • ACR Convergence 2025
Myositis Induced by Histidyl-Transfer tRNA Synthetase is Exacerbated by Membranopathy and Suppressed by Regulatory T Cells
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune disorders targeting muscle as well as extra-muscular organs. Among the most common autoantibodies associated…Abstract Number: 0280 • ACR Convergence 2025
Sera from dermatomyositis patients induce muscle weakness via activation of type I interferon (IFN) receptors.
Background/Purpose: Dermatomyositis (DM) is a major subtype of idiopathic inflammatory myopathies (IIMs) and characterized by muscle weakness, systemic inflammation and cutaneous lesions. Expression of type…Abstract Number: 0026 • ACR Convergence 2025
Spatial Proteomic-based Phenotyping of Muscle Stem Cells and their Niches in Myositis
Background/Purpose: Immune-mediated inflammatory myopathies (IIMs) are a heterogeneous group of diseases characterized by chronic inflammation, damage and impaired regeneration of the skeletal muscle leading to…Abstract Number: 2085 • ACR Convergence 2024
The Effects of Pioglitazone on Metabolic Dysregulation in Inclusion Body Myositis: An Open-Label Pilot Study
Background/Purpose: Inclusion body myositis (IBM) is a progressive muscle disease for which there is no effective treatment. Mitochondrial dysregulation is a pathologic hallmark of IBM.…Abstract Number: 2669 • ACR Convergence 2024
Dysferlin Autoantibodies Compromise Sarcolemmal Repair Capacity and Contribute to the Pathogenesis of Idiopathic Immune Myopathies
Background/Purpose: Idiopathic immune myopathies (IIMs) are a group of autoimmune diseases that produce chronic inflammation and degeneration of skeletal muscle structure and function. One process…Abstract Number: 2670 • ACR Convergence 2024
Sera from Patients with Idiopathic Inflammatory Myopathy Induces Muscle Weakness, Mitochondrial Dysfunction and Induction of Cytokines in Isolated Skeletal Muscle
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of systemic autoimmune inflammatory muscle disorders characterized by symmetrical skeletal muscle weakness and accelerated fatigue. Although signs…Abstract Number: 0163 • ACR Convergence 2024
Modification of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis, Clinically Amyopathic Dermatomyositis, and Immune-mediated Necrotizing Myopathy
Background/Purpose: The 2017 ACR/EULAR classification criteria for idiopathic inflammatory myopathies (IIM) currently used in myositis clinical trials/research demonstrated 87% sensitivity and 82% specificity for a…Abstract Number: 0320 • ACR Convergence 2024
Comparative Transcriptional Profiling Reveals Shared Pathway Activation Between Human Jo-1+ Anti-Synthetase Syndrome and Murine Histidyl-tRNA Synthetase-Induced Myositis
Background/Purpose: Previous work has shown unique gene expression profiles in muscle tissue corresponding to the anti-synthetase syndrome, with an emphasis on interferon gene signatures (Type…Abstract Number: 0326 • ACR Convergence 2024
Validity and Responsiveness of Core Set Measures in Idiopathic Inflammatory Myositis Based on 36-item Short Form Health Survey (SF-36)
Background/Purpose: There are six core set measures (CSMs) of disease activity in patients with idiopathic inflammatory myopathies (IIM). However, there is limited data on their…Abstract Number: 1735 • ACR Convergence 2024
High-Intensity Interval Training Outperforms Moderate Exercise in Aerobic Capacity for Recent-Onset Idiopathic Inflammatory Myopathies: A Randomized Controlled Trial
Background/Purpose: Exercise is a recognized adjunctive therapy for patients with idiopathic inflammatory myopathies (IIM), enhancing physical capacity and reducing inflammation. Hitherto, moderate-to-intensive exercise has been…Abstract Number: 1779 • ACR Convergence 2024
Single-Nuclear RNA-Sequencing of Treatment Naïve JDM Muscle Highlights Dysregulated Vascular Integrity and Angiogenesis in Endothelial Cells and Decreased Nitric Oxide Synthase Signaling in Type II Muscle Fibers
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children, and it frequently follows a chronic disease course. Treatments are limited secondary…